Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors

Cell Cycle

Volumn 12, Issue 17, 2013, Pages 2829-2838

  Ierano, Caterina ^a   Chakraborty, Arup R ^a   Nicolae, Alina ^a   Bahr, Julian C ^a   Zhan, Zhirong ^a   Pittaluga, Stefania ^a   Bates, Susan E ^a   Robey, Robert W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bak; Bax; Histone deacetylase inhibitor; Romidepsin; Vorinostat

Indexed keywords

ALISERTIB; BELINOSTAT; BIOLOGICAL MARKER; HISTONE DEACETYLASE INHIBITOR; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PANOBINOSTAT; PROTEIN BAK; PROTEIN BAX; ROMIDEPSIN; TOZASERTIB; VORINOSTAT;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRESCHOOL CHILD; PROTEIN EXPRESSION; TREATMENT RESPONSE; WILD TYPE;

BAK; BAX; HISTONE DEACETYLASE INHIBITOR; ROMIDEPSIN; VORINOSTAT;

ACETYLATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; AURORA KINASES; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BURKITT LYMPHOMA; CELL LINE, TUMOR; CHILD; DEPSIPEPTIDES; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; TIME FACTORS; YOUNG ADULT;

EID: 84883565304     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.25914     Document Type: Article

References (57)

1. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25:3109-15; PMID:17577020; http://dx.doi.org/10.1200/JCO.2006.10.2434
2. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27:5410-7; PMID:19826128; http://dx.doi.org/10.1200/JCO.2008.21.6150
3. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 2011; 117:5827-34; PMID:21355097; http://dx.doi.org/10.1182/blood-2010-10-312603
4. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 2012; 30:631-6; PMID:22271479; http://dx.doi.org/10.1200/JCO.2011.37.4223
5. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28:4485-91; PMID:20697094; http://dx.doi.org/10.1200/JCO.2010.28.9066
6. Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, et al. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29:1198-203; PMID:21300924; http://dx.doi.org/10.1200/JCO.2010.32.1398
7. Younes A, Oki Y, Bociek RG, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2011; 12:1222-8; PMID:22033282; http://dx.doi.org/10.1016/S1470-2045(11)70265-0
8. Giles F, Fischer T, Cortes J, Garcia-Manero G, Beck J, Ravandi F, Masson E, Rae P, Laird G, Sharma S, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2006; 12:4628-35; PMID:16899611; http://dx.doi.org/10.1158/1078-0432.CCR-06-0511
9. Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem 2012; 4:505-24; PMID:22416777; http://dx.doi.org/10.4155/fmc.12.3
10. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009; 15:3947-57; PMID:19509170; http://dx.doi.org/10.1158/1078-0432.CCR-08-2787
11. Robey RW, Chakraborty AR, Basseville A, Luchenko V, Bahr J, Zhan Z, Bates SE. Histone deacetylase inhibitors: emerging mechanisms of resistance. Mol Pharm 2011; 8:2021-31; PMID:21899343; http://dx.doi.org/10.1021/mp200329f
12. Chakraborty AR, Robey RW, Luchenko VL, Zhan Z, Piekarz RL, Gillet JP, Kossenkov AV, Wilkerson J, Showe LC, Gottesman MM, et al. MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor. Blood 2013; 121:4115-25; PMID:23532732; http://dx.doi.org/10.1182/blood-2012-08-449140
13. Venkannagari S, Fiskus W, Peth K, Atadja P, Hidalgo M, Maitra A, Bhalla KN. Superior efficacy of cotreatment with dual PI3K/mTOR inhibitor NVPBEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. Oncotarget 2012; 3:1416-27; PMID:23232026
14. Shao Y, Aplin AE. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ 2012; 19:2029-39; PMID:22858545; http://dx.doi.org/10.1038/cdd.2012.94
15. Stauber RH, Knauer SK, Habtemichael N, Bier C, Unruhe B, Weisheit S, Spange S, Nonnenmacher F, Fetz V, Ginter T, et al. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget 2012; 3:31-43; PMID:22289787
16. Aron JL, Parthun MR, Marcucci G, Kitada S, Mone AP, Davis ME, Shen T, Murphy T, Wickham J, Kanakry C, et al. Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein. Blood 2003; 102:652-8; PMID:12649137; http://dx.doi.org/10.1182/blood-2002-12-3794
17. Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, Banks KM, Haynes NM, Gangatirkar P, Stanley K, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 2008; 105:11317-22; PMID:18685088; http://dx.doi.org/10.1073/pnas.0801868105
18. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, Grant S. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999; 18:7016-25; PMID:10597302; http://dx.doi.org/10.1038/sj.onc.1203176
19. Newbold A, Lindemann RK, Cluse LA, Whitecross KF, Dear AE, Johnstone RW. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Mol Cancer Ther 2008; 7:1066-79; PMID:18483296; http://dx.doi.org/10.1158/1535-7163.MCT-07-2256
20. Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 2002; 64:1079-90; PMID:12234611; http://dx.doi.org/10.1016/S0006-2952(02)01261-3
21. Hartlapp I, Pallasch C, Weibert G, Kemkers A, Hummel M, Re D. Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines. Leuk Res 2009; 33:929-36; PMID:19233470; http://dx.doi.org/10.1016/j.leukres.2008.12.013
22. Lindemann RK, Newbold A, Whitecross KF, Cluse LA, Frew AJ, Ellis L, Williams S, Wiegmans AP, Dear AE, Scott CL, et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc Natl Acad Sci U S A 2007; 104:8071-6; PMID:17470784; http://dx.doi.org/10.1073/pnas.0702294104
23. Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, Torrico S, Bates SE. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004; 103:4636-43; PMID:14996704; http://dx.doi.org/10.1182/blood-2003-09-3068
24. Sander S, Rajewsky K. Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells. Oncotarget 2012; 3:1066-7; PMID:23164662
25. Calado DP, Sasaki Y, Godinho SA, Pellerin A, Köchert K, Sleckman BP, de Alborán IM, Janz M, Rodig S, Rajewsky K. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol 2012; 13:1092-100; PMID:23001146; http://dx.doi.org/10.1038/ni.2418
26. Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ, Blum KA, Hofmeister CC, Freitas MA, Parthun MR, et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010; 5:e10941; PMID:20532179; http://dx.doi.org/10.1371/journal. pone.0010941
27. Sculley TB, Buck M, Gabrielli B, Parsons PG, Krauer KG. A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease. Transplantation 2002; 73:271-9; PMID:11821743; http://dx.doi.org/10.1097/00007890-200201270-00021
28. Wang R, Brunner T, Zhang L, Shi Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene 1998; 17:1503-8; PMID:9794227; http://dx.doi.org/10.1038/sj.onc.1202059
29. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718-28; PMID:11895901
30. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002; 94:504-13; PMID:11929951; http://dx.doi.org/10.1093/jnci/94.7.504
31. Xiao JJ, Huang Y, Dai Z, Sadée W, Chen J, Liu S, Marcucci G, Byrd J, Covey JM, Wright J, et al. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-di i sopropyl-2-ox a-12,13-di thi a-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines. J Pharmacol Exp Ther 2005; 314:467-75; PMID:15833893; http://dx.doi.org/10.1124/jpet.105.083956
32. Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin Cancer Res 2006; 12:1547-55; PMID:16533780; http://dx.doi.org/10.1158/1078- 0432.CCR-05-1423
33. Ueda H, Nakajima H, Hori Y, Goto T, Okuhara M. Action of FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum no. 968, on Ha-ras transformed NIH3T3 cells. Biosci Biotechnol Biochem 1994; 58:1579-83; PMID:7765477; http://dx.doi.org/10.1271/bbb.58.1579
34. Mori N, Ishikawa C, Senba M, Kimura M, Okano Y. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas. Biochem Pharmacol 2011; 81:1106-15; PMID:21371446; http://dx.doi.org/10.1016/j. bcp.2011.02.010
35. Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A. Analysis of Aurora B kinase in non-Hodgkin lymphoma. Lab Invest 2009; 89:1364-73; PMID:19823168; http://dx.doi.org/10.1038/labinvest.2009.106
36. Shao W, Growney JD, Feng Y, O'Connor G, Pu M, Zhu W, Yao YM, Kwon P, Fawell S, Atadja P. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance. Int J Cancer 2010; 127:2199-208; PMID:20127862; http://dx.doi.org/10.1002/ijc. 25218
37. Gutiérrez MI, Cherney B, Hussain A, Mostowski H, Tosato G, Magrath I, Bhatia K. Bax is frequently compromised in Burkitt's lymphomas with irreversible resistance to Fas-induced apoptosis. Cancer Res 1999; 59:696-703; PMID:9973220
38. Li M, Jung A, Ganswindt U, Marini P, Friedl A, Daniel PT, Lauber K, Jendrossek V, Belka C. Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways. Biochem Pharmacol 2010; 79:122-9; PMID:19686703; http://dx.doi.org/10.1016/j.bcp.2009.08.011
39. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001; 292:727-30; PMID:11326099; http://dx.doi.org/10.1126/science.1059108
40. Wang C, Youle RJ. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1's inhibitory effect on Bak. Oncogene 2012; 31:3177-89; PMID:22056880
41. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, Perucho M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 1997; 275:967-9; PMID:9020077; http://dx.doi.org/10.1126/science.275.5302.967
42. Ouyang H, Furukawa T, Abe T, Kato Y, Horii A. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res 1998; 4:1071-4; PMID:9563904
43. Percesepe A, Kristo P, Aaltonen LA, Ponz de Leon M, de la Chapelle A, Peltomäki P. Mismatch repair genes and mononucleotide tracts as mutation targets in colorectal tumors with different degrees of microsatellite instability. Oncogene 1998; 17:157-63; PMID:9674699; http://dx.doi.org/10.1038/ sj.onc.1201944
44. Vassileva V, Millar A, Briollais L, Chapman W, Bapat B. Genes involved in DNA repair are mutational targets in endometrial cancers with microsatellite instability. Cancer Res 2002; 62:4095-9; PMID:12124347
45. Brimmell M, Mendiola R, Mangion J, Packham G. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 1998; 16:1803-12; PMID:9583678; http://dx.doi.org/10.1038/sj.onc.1201704
46. Corso G, Pedrazzani C, Marrelli D, Pascale V, Pinto E, Roviello F. Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma. Arch Surg 2009; 144:722-7; PMID:19687375; http://dx.doi.org/10.1001/archsurg.2009.42
47. Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol 2011; 5:385-99; PMID:21651356; http://dx.doi.org/10.1586/egh.11.25
48. Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A 2000; 97:10872-7; PMID:10984511; http://dx.doi.org/10.1073/pnas.190210897
49. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55:4471-8; PMID:7671262
50. Jeong SH, Han JH, Kim JH, Ahn MS, Hwang YH, Lee HW, Kang SY, Park JS, Choi JH, Lee KJ, et al. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy. Dig Dis Sci 2011; 56:131-8; PMID:20503071; http://dx.doi.org/10.1007/s10620-010- 1280-8
51. Kang SY, Han JH, Lee KJ, Choi JH, Park JI, Kim HI, Lee HW, Jang JH, Park JS, Kim HC, et al. Low expression of Bax predicts poor prognosis in patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy. Clin Cancer Res 2007; 13:4146-53; PMID:17634542; http://dx.doi.org/10.1158/1078-0432.CCR-06-3063
52. Hussain SA, Ganesan R, Hiller L, Murray PG, el-Magraby MM, Young L, James ND. Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. Br J Cancer 2003; 88:586-92; PMID:12592374; http://dx.doi.org/10.1038/sj.bjc.6600765
53. Ong YL, McMullin MF, Bailie KE, Lappin TR, Jones FG, Irvine AE. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Haematol 2000; 111:182-9; PMID:11091199; http://dx.doi.org/10.1046/j.1365-2141. 2000.02315.x
54. Magrath I. Epidemiology: clues to the pathogenesis of Burkitt lymphoma. Br J Haematol 2012; 156:744-56; PMID:22260300; http://dx.doi.org/10.1111/j.1365- 2141.2011.09013.x
55. Magrath I. Towards curative therapy in burkitt lymphoma: the role of early african studies in demonstrating the value of combination therapy and CNS prophylaxis. Adv Hematol 2012; 2012:130680; PMID:22287968; http://dx.doi.org/10. 1155/2012/130680
56. Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D, Shipp M. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004; 45:761-7; PMID:15160953; http://dx.doi.org/10.1080/1042819031000141301
57. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science 2000; 290:989-92; PMID:11062132; http://dx.doi.org/10.1126/science.290.5493.989